Zealand Pharma Signs Licensing Agreement with Novo Nordisk for Zegalogue®

By Ayush Saxena

Pharma Deals Review: Vol 2022 Issue 9 (Table of Contents)

Published: 21 Sep-2022

DOI: 10.3833/pdr.v2022.i9.2722     ISSN: 1756-7874

Section: Licensing



Zealand Pharma has entered into a global license and development agreement with Novo Nordisk to commercialise its low blood sugar therapy, Zegalogue®(dasiglucagon), for injection...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details